Neoadjuvant Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Neoadjuvant PSMA-RLT in Oligometastatic PCa
Conditions: Prostate Cancer Interventions: Drug: [177Lu]Lu-PSMA I&T Sponsors: Medical University of Vienna Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials

NEOadjuvant Abemaciclib and GIredestrant triaL in Patients With ER-positive, HER2-negative Early Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Abemaciclib 150 MG + Giredestrant 30 MG Sponsors: Fondazione Oncotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
Conditions: Limited Stage Small Cell Lung Cancer Interventions: Drug: JS004; Drug: Toripalimab; Procedure: surgery; Drug: Etoposide; Drug: Platinum Sponsors: Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
Conditions: Rectal Cancer; Rectal Cancer Stage II; Rectal Cancer Stage III Interventions: Drug: Tislelizumab combined with chemotherapy Sponsors: First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
Conditions: PD-1; Neoadjuvant Chemoradiotherapy; Gastroesophageal Junction Cancer Interventions: Drug: PD-1inhibitor Sponsors: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials

Study for Wait and Watch Suitable for Rectal Cancer
Conditions: Rectal Neoplasms Interventions: Other: Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose Sponsors: Tata Memorial Centre Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials

MRI Guided SIB Radiotherapy in Neoadjuvant Therapy for Advanced Rectal Cancer
Conditions: Rectal Cancer Interventions: Radiation: MRI Guided Simultaneous Integrated Boost Radiotherapy Sponsors: Shandong Cancer Hospital and Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Conditions: Triple Negative Breast Cancer Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Olaparib; Drug: Capecitabine Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials

Efficacy and Safety of NSCLC Patients With/Without Adjuvant Immunotherapy Who Have Achieved pCR After Neoadjuvant Immunotherapy
Conditions: Resectable/Potentially Resectable NSCLC Interventions: Drug: Immunotherapy Sponsors: Xiangya Hospital of Central South University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials

Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Other: non-intervention Sponsors: Tianjin Medical University Cancer Institute and Hospital; Chinese Academy of Medical Sciences; Sichuan Cancer Hospital and Research Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
Conditions: IMMUNOTHERAPY; Neoadjuvant Therapy; Resectable Lung Non-Small Cell Carcinoma; Biomarkers / Blood Interventions: Drug: Camrelizumab Plus Chemotherapy Sponsors: Shandong Cancer Hospital and Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials

Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Conditions: Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer Interventions: Drug: Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy Sponsors: Yunnan Cancer Hospital; Beijing Bethune Charitable Foundation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinomas; Resectable Head and Neck Squamous-cell Carcinoma Interventions: Drug: Tislelizumab; Drug: Nab-paclitaxel; Drug: Carboplatin Sponsors: Xiang Lu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Conditions: Recurrent Nasopharyngeal Carcinoma Interventions: Procedure: endoscopic surgery; Drug: Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy; Drug: Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy; Drug: Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy Sponsors: Eye& ENT Hospital of Fudan University; Shanghai Zhongshan Hospital; Shanghai 6th People ' s Hospital; Changhai Hospital; Fujian Medical University Union Hospital; People ' s Hospital of Guangxi; Shenzhen Second People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials

Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Conditions: Pancreatic Cancer Interventions: Drug: Astragalus + Gemcitabine; Drug: Gemcitabine alone Sponsors: Shenzhen University General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials